Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

BACKGROUND: Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Excellence (NICE) preli...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zhong, Lixian, Pon, Vickie, Srinivas, Sandy, Nguyen, Nicole, Frear, Meghan, Kwon, Sherry, Gong, Cynthia, Malmstrom, Robert, Wilson, Leslie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661482/
https://ncbi.nlm.nih.gov/pubmed/23717582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0064275
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller